title: New bradykinin analogues modified in the C-terminal part with sterically restricted 1-aminocyclohexane-1-carboxylic acid.
abstract: In the present work, a sterically constrained noncoded amino acid, 1-aminocyclohexane-1-carboxylic acid (Acc), was substituted in position 8 of the peptide chain of bradykinin (BK) and position 6, 7, or 8 of its B2 receptor antagonist [D-Arg0,Hyp3,Thi,(5,8)D-Phe7]BK, previously synthesized by Stewart's group, to reduce the flexibility of the peptides, thus forcing the peptide backbone and side chains to adopt specific orientations. Knowing that acylation of the N-terminus of several known B2 blockers with a variety of bulky groups has consistently improved their antagonistic potency in the rat blood pressure assay, the Acc substituted analogues were also synthesized in the N-acylated form with 1-adamantaneacetic acid (Aaa). The activity of eight new analogues was assayed in isolated rat uterus and in rat blood pressure tests. The results clearly demonstrated the importance of the position in the peptide chain into which the sterically restricted Acc residue was inserted. Meanwhile, Acc at positions 6 and 7 led to reduction of antagonistic qualities or even restored the agonism, respectively. Acc at position 8 enhanced antagonistic qualities in both tests. The Acc at position 8 of BK strongly reduced the agonistic potency. In most cases acylation of the N-terminus led either to enhancement of antagonistic potencies or to further decrease of agonistic potency. Our findings offer new possibilities for designing new potent and selective B2 blockers.
authors.affiliation: Faculty of Chemistry, University of Gdańsk, Sobieskiego 18, 80-952 Gdańsk, Poland. olad@chemik.chem.univ.gda.pl
authors.forename: Olga
authors.initials: O
authors.lastname: Labudda-Dawidowska
authors.forename: Tomasz H
authors.initials: TH
authors.lastname: Wierzba
authors.forename: Adam
authors.initials: A
authors.lastname: Prahl
authors.forename: Wioleta
authors.initials: W
authors.lastname: Kowalczyk
authors.forename: Łukasz
authors.initials: Ł
authors.lastname: Gawiński
authors.forename: Marketa
authors.initials: M
authors.lastname: Plackova
authors.forename: Jirina
authors.initials: J
authors.lastname: Slaninová
authors.forename: Bernard
authors.initials: B
authors.lastname: Lammek
mesh_terms: D000085:Acetates / Q000737:chemistry; D000218:Adamantane / Q000031:analogs & derivatives / Q000737:chemistry; D000598:Amino Acids, Cyclic / Q000737:chemistry*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000138:chemical synthesis* / Q000494:pharmacology; D065094:Bradykinin B2 Receptor Antagonists; D003509:Cyclohexanecarboxylic Acids / Q000737:chemistry*; D005260:Female; D066298:In Vitro Techniques; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D043782:Receptor, Bradykinin B2 / Q000819:agonists; D013329:Structure-Activity Relationship; D014590:Uterine Contraction / Q000187:drug effects
chemical_list: C507636:1-adamantaneacetic acid; D000085:Acetates; D000598:Amino Acids, Cyclic; D065094:Bradykinin B2 Receptor Antagonists; D003509:Cyclohexanecarboxylic Acids; D043782:Receptor, Bradykinin B2; C014966:1-aminocyclohexanecarboxylic acid; D000218:Adamantane; D001920:Bradykinin